Sutro Biopharma Inc. (STRO)
0.62
0.02 (4.15%)
At close: Apr 02, 2025, 3:59 PM
0.62
0.17%
After-hours: Apr 02, 2025, 07:00 PM EDT
4.15% (1D)
| Bid | 0.61 |
| Market Cap | 51.64M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -2.96 |
| PE Ratio (ttm) | -0.21 |
| Forward PE | -0.55 |
| Analyst | Buy |
| Ask | 0.63 |
| Volume | 1,016,407 |
| Avg. Volume (20D) | 1,352,210 |
| Open | 0.59 |
| Previous Close | 0.60 |
| Day's Range | 0.59 - 0.68 |
| 52-Week Range | 0.58 - 5.70 |
| Beta | 1.22 |
About STRO
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-H...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 27, 2018
Employees 310
Stock Exchange NASDAQ
Ticker Symbol STRO
Website https://www.sutrobio.com
Analyst Forecast
According to 8 analyst ratings, the average rating for STRO stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 1522.32% from the latest price.
Stock ForecastsNext Earnings Release
Sutro Biopharma Inc. is scheduled to release its earnings on May 12, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
-35.19%
Sutro Biopharma shares are trading lower after B o...
Unlock content with
Pro Subscription
4 months ago
-12.88%
Sutro Biopharma shares are trading lower after the company reported worse-than-expected Q3 sales results.
